Immune checkpoint inhibitors (ICIs), including the programmed death-1 (PD-1) and the programmed death-ligand 1 (PD-L1), have exhibited potential therapeutic effects for advanced HCC (11–13). The gene discussed is CD274; the disease is hepatocellular carcinoma.